ADVANCED ACCELERATOR APPLICATIONS

๐Ÿ‡ซ๐Ÿ‡ทFrance
Ownership
-
Established
2002-01-01
Employees
-
Market Cap
-
Website
http://www.adacap.com

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-07-28
Last Posted Date
2019-12-13
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
5
Registration Number
NCT03232580
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cedars Sinai Medical Center, Los Angeles, California, United States

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

First Posted Date
2016-03-10
Last Posted Date
2018-04-09
Lead Sponsor
Advanced Accelerator Applications
Registration Number
NCT02705313
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California, San Francisco, San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California, Los Angeles, Los Angeles, California, United States

and more 37 locations

99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer

First Posted Date
2016-02-09
Last Posted Date
2020-12-11
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
14
Registration Number
NCT02677714
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2016-01-29
Last Posted Date
2020-10-09
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
39
Registration Number
NCT02667457
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)

First Posted Date
2014-12-31
Last Posted Date
2020-10-08
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
16
Registration Number
NCT02328027
Locations
๐Ÿ‡จ๐Ÿ‡ญ

Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers

First Posted Date
2014-07-08
Last Posted Date
2019-11-21
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
14
Registration Number
NCT02182609
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

The University of Ottawa Heart Institute, Ottawa, Ontario, Canada

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

First Posted Date
2012-04-16
Last Posted Date
2022-04-04
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
231
Registration Number
NCT01578239
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kettering Medical Center, Kettering, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwestern Medical Faculty Foundation, Chicago, Illinois, United States

and more 36 locations

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison

First Posted Date
2011-06-23
Last Posted Date
2014-05-14
Lead Sponsor
Advanced Accelerator Applications
Target Recruit Count
135
Registration Number
NCT01379677
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

University College Hospital London NHS Foundation Trust, London, United Kingdom

ยฉ Copyright 2024. All Rights Reserved by MedPath